Shire receives FDA approval for ADHD drug
Shire claims that unlike some other ADHD treatments, Intuniv is not a controlled substance and does not have a known mechanism for potential abuse or dependence. “The information
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).